<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434456</url>
  </required_header>
  <id_info>
    <org_study_id>C-HEAL</org_study_id>
    <nct_id>NCT04434456</nct_id>
  </id_info>
  <brief_title>Carotid Artery Aneurysm Treatment Using CGuard Divert-And-Heal Strategy</brief_title>
  <acronym>C-HEAL</acronym>
  <official_title>Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Paul II Hospital, Krakow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Paul II Hospital, Krakow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, single arm, open label, academic observational study of CGuard MicroNet&#xD;
      covered stent system use to achieve endovascular lumen reconstruction in carotid artery&#xD;
      aneurysms with indications for treatment (enlarging and/or dissecting / symptomatic).&#xD;
&#xD;
      Jagiellonian University Medical College research project.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carotid artery aneurysm (CAA) is a relatively infrequent, but significant clinical condition&#xD;
      with numerous diagnostic and therapeutic implications. CAA affects laminal flow in the&#xD;
      carotid artery implicating the risk of thrombus formation in the aneurysm cavity, and&#xD;
      subsequent ischemic stroke from distal embolization. Another important clinical problem&#xD;
      related to the CAA is a possible aneurysm dissection and rupture. Symptomatic CAA and&#xD;
      increasing dimensions of CAA institute unquestioned indications for the CAA treatment.&#xD;
&#xD;
      Surgical carotid aneurysm repair bears a significant risk (periprocedural stroke, cranial&#xD;
      nerve damage, carotid artery ligation). Therefore endovascular techniques of CAA exclusion&#xD;
      were developed. Covered stents, stent-grafts, and combined stenting and aneurysm embolization&#xD;
      with coils were applied. However, covered stents were demonstrated to increase the restenosis&#xD;
      risk, and other complications such as CAA neck endo-leak.&#xD;
&#xD;
      Newer technique involves the flow diversion by implantation of stent in dense-structured&#xD;
      stent (such as Wallstent) or stent-in-stent implantation. In this case a luminary flow&#xD;
      dominates over aneurysm filling, which is limited by stent structure. Gradual thrombosis and&#xD;
      occlusion of aneurysm cavity and healing of aneurysm follows.This method disadvantage was&#xD;
      related to necessity of double stent load and increased restenosis risk (double metal layer).&#xD;
&#xD;
      These issues were addressed only recently by the double layer mesh stents that demonstrate&#xD;
      natural flow diverting capabilities. CGuard Stent system is a self-expandable stent covered&#xD;
      with PET mesh (MicroNet) that prevents plaque protrusion into the vessel lumen. In addition,&#xD;
      in low flow conditions MicroNet can act as the flow diverter. These stents are routinely&#xD;
      implanted in elevated risk plaques in high reference centers in Europe.&#xD;
&#xD;
      Several published observations indicate the CGuard stent also demonstrates flow-diverting&#xD;
      capabilities, but the systematic observation of such application was not performed.&#xD;
&#xD;
      C-HEAL is a non-randomized, single arm, open label academic observational study of CGuard&#xD;
      stent implantation in carotid arteries in patients with symptomatic, dissecting or enlarging&#xD;
      carotid artery aneurysm. Procedures are performed according to the center routine, with&#xD;
      application of proximal or distal embolic protection device (if feasible), and standard&#xD;
      pharmacotherapy according to the current guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful aneurysm exclusion</measure>
    <time_frame>6 months</time_frame>
    <description>Successful aneurysm cavity exclusion and endovascular lumen reconstruction on routine, non-invasive CT angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of procedural success</measure>
    <time_frame>Peri-procedural</time_frame>
    <description>Procedural success defined as: Technical success (successful MicroNet covered stent delivery and implantation with complete aneurysm necks coverage) and Clinical success (no complications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of In-hospital MACNE (major adverse cardiac and neurological events)</measure>
    <time_frame>48 hrs or until discharge</time_frame>
    <description>In-hospital MACNE (death, stroke, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACNE at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>MACNE at 30 days (death, stroke, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of peri-procedural complications</measure>
    <time_frame>48 hrs or until discharge</time_frame>
    <description>Any complications occurring up to 48 hours post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical efficacy at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical efficacy at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in the target vessel segment</measure>
    <time_frame>6 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment</measure>
    <time_frame>12 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment</measure>
    <time_frame>24 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Carotid Artery Aneurysm</condition>
  <arm_group>
    <arm_group_label>CGuard stenting (interventional)</arm_group_label>
    <description>CGuard implantation in the carotid artery with aneurysm requiring intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGuard stent implantation</intervention_name>
    <description>CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm</description>
    <arm_group_label>CGuard stenting (interventional)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        10 to 25 patients meeting inclusion and exclusion criteria and evaluated by Vascular Team&#xD;
        to receive an endovascular treatment for carotid artery aneurysm&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        General&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years, eligible for endovascular carotid artery aneurysm&#xD;
             treatment with Micronet covered stent per Vascular Team evaluation, according to local&#xD;
             standards&#xD;
&#xD;
          -  Written, informed consent to participate&#xD;
&#xD;
          -  Agreement to attend protocol required (standard) follow up visits and examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preferred treatment other than stenting (surgery or conservative treatment /&#xD;
             observation) per Vascular Team evaluation&#xD;
&#xD;
          -  Life expectancy &lt;1 year (e.g. active neoplastic disease).&#xD;
&#xD;
          -  Chronic kidney disease with creatinine &gt; 3.0 mg/dL.&#xD;
&#xD;
          -  Myocardial infarction in 72 hours proceeding the stenting procedure (if possible,&#xD;
             postponing the procedure)&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test)&#xD;
&#xD;
          -  Coagulopathy.&#xD;
&#xD;
          -  History of uncontrolled contrast media intolerance&#xD;
&#xD;
        Angiographic&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Carotid artery aneurysm confirmed on angiography - symptomatic, dissected or enlarging&#xD;
&#xD;
          -  Aneurysm eligible for endovascular treatment per Vascular Team evaluation (according&#xD;
             to current standards, guidelines and study center practice)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unsuccessful true lumen engagement&#xD;
&#xD;
          -  Aneurysm neck anatomy precluding healthy-to-healthy coverage with stent&#xD;
&#xD;
          -  Anatomic variants precluding stent implantation&#xD;
&#xD;
          -  Mobile (free-floating) plaque elements in aorta or arteries proximal to target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Musialek, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>The John Paul II Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Musialek, MD, DPhil</last_name>
    <phone>+48126142287</phone>
    <email>p.musialek@szpitaljp2.krakow.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiac and Vascular Diseases, The John Paul II Hospital</name>
      <address>
        <city>Krak√≥w</city>
        <state>Maloplska</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Musialek, Prof</last_name>
      <phone>+48126142287</phone>
      <email>p.musialek@szpitaljp2.krakow.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

